The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer
| Autor: | Michael V. Di Maria, E. David Crawford, Marileila Varella-Garcia, Patrapim Sunpaweravong, Bulent Akduman |
|---|---|
| Přispěvatelé: | Zonguldak Bülent Ecevit Üniversitesi |
| Rok vydání: | 2003 |
| Předmět: |
Neoplasm recurrence
Male Pathology medicine.medical_specialty Urology Pilot Projects Urine Urinalysis Sensitivity and Specificity Fluorescence Cytology medicine Humans Mass Screening Prospective Studies Mass screening In Situ Hybridization Fluorescence Urine cytology Abnormal Urine Cytology Aged Aged 80 and over Bladder neoplasms Bladder cancer Urinary bladder medicine.diagnostic_test business.industry Cystoscopy Middle Aged Cytogenetic analysis medicine.disease medicine.anatomical_structure Oncology Urinary Bladder Neoplasms Female Neoplasm Recurrence Local business In situ hybridization Molecular diagnostic techniques Fluorescence in situ hybridization |
| Zdroj: | Urologic oncology. 22(1) |
| ISSN: | 1078-1439 |
| Popis: | The newly developed UroVysion fluorescence in situ hybridization (FISH) probe was applied to urine specimens from 19 patients being monitored for recurrence of bladder cancer. The results for the multi-target DNA FISH assay were compared with independent analyses of urine cytology and flexible cystoscopy. Patients with tumors identified through the cystoscopy exam were biopsied and/or underwent surgery. In 12 patients with normal cytoscopy, cytology and FISH were also normal. Therefore, the specificity of these two tests was 100%. In 7 patients, a tumor was diagnosed by cystoscopy, and 3 of them had abnormal urine cytology while 6 of them had an abnormal result in the FISH assay. Accordingly, the sensitivity was 43% for the cytology and 87% for the FISH test. Interestingly, a pT1G3 tumor in a bladder diverticulum was not detected by cytology or the FISH test. These results agreed with a large series previously published using similar FISH probes and support the proposal for a multicenter trial to confirm the usefulness of the UroVysion probe as a screening tool to select patients for cystoscopy. © 2004 Elsevier Inc. All rights reserved. National Cancer Institute: P30-CA46934 Cancer Center, University of Colorado The authors acknowledge Vysis Inc. (Downers Grove, IL) for providing a UroVysion kit for optimization of the FISH protocol. The study was partially supported by the National Cancer Institute Grant P30-CA46934 to the University of Colorado Cancer Center. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect